The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
- Advertisement -
APLICATIONS
Older Americans using AI to save on summer travel, AARP study...
With fuel prices surging and budgets stretched, many Americans are rethinking their summer travel plans — but a new study from AARP suggests adults...
